MME
ENSG00000196549
Target class
Enzyme
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
4
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- No
- Target name
- MME
- Gene name
- Membrane metalloendopeptidase
- Gene symbol
- MME
- Protein name
- Neprilysin (EC 3.4.24.11) (Atriopeptidase) (Common acute lymphocytic leukemia antigen) (CALLA) (Enkephalinase) (Neutral endopeptidase 24.11) (NEP) (Neutral endopeptidase) (Skin fibroblast elastase) (SFE) (CD antigen CD10)
- CALLA
- CD10
- NEP
- Gene biotype
- Protein coding
- Gene family
- CD molecules|M13 metallopeptidases|Elastases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 29
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 640.48
- Tissue specificity (Gini)
- 0.894
- Tissue specificity (tau)
- 0.991
- KEGG gene identifiers
- hsa:4311
- Protein interaction confidence
- 0.814414
- Protein interaction partners
- 58
- R-HSA-2022377
- R-HSA-5578768
- R-HSA-6798695
- R-HSA-9927432
- End position
- 155183803
- Start position
- 155024124
- Chromosome
- 3
- Strand
- Forward
- Cell membrane
- Single-pass type II membrane protein .
- Plasma membrane
Publication evidence
- PubMed 20876573
- Tissue specificity (tau)
- 0.991303
- Expression inequality (Gini)
- 0.893758
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 640.48
- Nerve - Tibial
- 42.94
- Kidney - Cortex
- 37.73
- Prostate
- 24.75
- Adipose - Subcutaneous
- 24.01
Expression in transcripts per million
- Cells - Cultured fibroblasts640.48
- Nerve - Tibial42.94
- Kidney - Cortex37.73
- Prostate24.75
- Adipose - Subcutaneous24.01
- Breast - Mammary Tissue22.29
- Whole Blood22.18
- Lung20.28
- Small Intestine - Terminal Ileum17.72
- Adipose - Visceral (Omentum)11.21
- Vagina7.78
- Muscle - Skeletal7.76
- Brain - Caudate (basal ganglia)5.84
- Liver5.81
- Kidney - Medulla5.6
- Minor Salivary Gland5.14
- Brain - Putamen (basal ganglia)4.33
- Esophagus - Gastroesophageal Junction2.76
- Spleen2.47
- Cervix - Ectocervix2.22
- Artery - Coronary2.07
- Bladder2.03
- Cervix - Endocervix1.84
- Fallopian Tube1.58
- Brain - Nucleus accumbens (basal ganglia)1.48
And 29 more, listed on the interactive page.
- GO:0001822
- GO:0006508
- GO:0007611
- GO:0010814
- GO:0010815
- GO:0042447
- GO:0046449
- GO:0050769
- GO:0061837
- GO:0071345
- GO:0071492
- GO:0071493
- GO:0090399
- GO:0097242
- GO:0150094
- GO:0005737
- GO:0005769
- GO:0005802
- GO:0005886
- GO:0005903
- GO:0005925
- GO:0030424
- GO:0030667
- GO:0031410
- GO:0043025
- GO:0045121
- GO:0070062
- GO:0098793
- GO:0001786
- GO:0004175
- GO:0004222
- GO:0005515
- GO:0008238
- GO:0008270
- GO:0042803
- GO:1901612
Related records
Trials (135)
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
- A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data
- A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
- A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
- A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
- A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension
- An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
- Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
- Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
- Anti-Secretory Drug in Treatment of Acute Watery Diarrhea
- ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling
- ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure
- AVE7688 in Patients With Mild to Moderate Blood Pressure
- Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults
- Bioequivalence Study of Generic Racecadotril 100 mg Capsules Under Fasting Conditions
- Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg)
Drugs (4)
- Daglutril Neprilysin inhibitor
- Ilepatril Neprilysin inhibitor
- Racecadotril Neprilysin inhibitor
- Sacubitril Neprilysin inhibitor